2-溴-3-氟-5-氯吡啶 | 514797-97-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-溴-3-氟-5-氯吡啶
• 中文别名: 2-溴-5-氯-3-氟吡啶
• 英文名称: 2-bromo-5-chloro-3-fluoropyridine
• CAS: 514797-97-8
• 化学式: C₅H₂BrClFN
• 分子量: 210.433
• InChiKey: PYDGFYYLQFJQBZ-UHFFFAOYSA-N

物化性质

• 沸点：
  190.8±35.0 °C(Predicted)
• 密度：
  1.829±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 2-8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-5-chloro-3-fluoropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-5-chloro-3-fluoropyridine
CAS number: 514797-97-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H2BrClFN
Molecular weight: 210.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride, hy-
drogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-3-氟-5-氯吡啶 在 2,2,6,6-四甲基哌啶 、 正丁基锂 、 硫酸 、 异丙基氯化镁 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 19.25h， 生成 methyl 6-bromo-3-chloro-5-fluoro-2-pyridinecarboxylate
  参考文献：
  名称：

  Creating Structural Manifolds from a Common Precursor: Basicity Gradient-Driven Isomerization of Halopyridines

  摘要：

  5-Chloro-2,3-difluoropyridine, an intermediate in the manufacturing process of an industrial pesticide, can be hydrolyzed to 5-chloro-3-fluoro-2H-pyridinone and the latter converted into 2,5-dichloro-3-fluoropyridine (1a), 2-bromo-5chloro-3-fluoropyridine (1b), 5-chloro-3-fluoro-2-iodopyridine (1c) and 3-chloro-5-fluoropyridine (1d). Consecutive treatment of these four substrates with lithium diisopropylamide and carbon dioxide or lithium diisopropylamide and iodine affords the corresponding 4-pyridinecarboxylic acids 2 and 4-iodopyridines 3, respectively. Amide-promoted deprotonation of such 4-iodopyridines 3 triggers an isomerization in which lithium and iodine change places. The resulting species can be trapped with carbon dioxide to give the acids 5a-c or neutralized to give the halopyridines 4a-c. The iodopyridines 4a and 4b can be converted into the acids 6a and 6b, the latter product leading also to the congeners 6c and 6d. The diiodopyridine 4c provides an entry to the halopyridine 4d, which at the same time may act as the precursor to the acid 5d, the acid 7 or the bisacid 8. Finally, the acid 9 is accessible from either one of the 5-chloro-3-fluoro-2-halopyridines 1b and 1c. (C) Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2002).

  DOI：

  10.1002/1099-0690(200212)2002:24<4174::aid-ejoc4174>3.0.co;2-6
• 作为产物：
  描述：

  5-氯-3-氟吡啶-2-醇 在 三溴氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以74%的产率得到2-溴-3-氟-5-氯吡啶
  参考文献：
  名称：

  Certain Chemical Entities, Compositions, and Methods

  摘要：

  提供了某些化学实体和使用方法，用于调节骨骼肌肌球蛋白、骨骼肌肌动蛋白、骨骼肌肌肽肌动蛋白、骨骼肌肌钙蛋白C、骨骼肌肌钙蛋白I、骨骼肌肌钙蛋白T和骨骼肌，包括其片段和同工异构体，以及骨骼肌肌节，以及在治疗肌无力和/或消瘦症、作为康复或锻炼计划的一部分，或在治疗虚弱、脊髓灰质炎后综合症、肥胖、肌少症、消耗综合症、肌肉痉挛和其他适应症中的使用方法。

  公开号：

  US20080242695A1

文献信息

• [EN] HERBICIDAL COMPOUNDS<br/>[FR] COMPOSÉS HERBICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2016062587A1

  公开（公告）日：2016-04-28

  The present invention relates to a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are as defined herein; and wherein the compound of formula (I) is optionally present as an agrochemically acceptable salt thereof. These compounds are suitable for use as herbicides. The invention therefore also relates to a method of controlling weeds, especially grassy monocotyledonous weeds, in crops of useful plants, comprising applying a compound of formula (I), or a herbicidal composition comprising such a compound, to the plants or to the locus thereof.

  本发明涉及一种具有式（I）的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11和G如本文所定义；以及其中化合物（I）可以作为其农药可接受的盐存在。这些化合物适用于用作除草剂。因此，本发明还涉及一种控制杂草的方法，特别是在有用植物的作物中控制禾本科杂草，包括将式（I）的化合物或包含这种化合物的除草剂组合物施用于植物或其生长地点。
• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE UK NO 5 LTD

  公开号：WO2021064677A1

  公开（公告）日：2021-04-08

  Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I.

  公式I的化合物，包括其药用可接受的盐，以及用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法如下：公式I。
• [EN] SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF<br/>[FR] BENZAMIDES SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2015078374A1

  公开（公告）日：2015-06-04

  The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  这项发明提供了具有一般式I的化合物及其药用盐，其中变量RA、RAA、下标n、环A、X2、L、下标m、X1、R1、R2、R3、R4、R5和RN的含义如本文所述，并包含这种化合物的组合物和使用这种化合物和组合物的方法。
• [EN] NOVEL GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] NOUVEAU GALACTOSIDE COMME INHIBITEUR DE GALECTINES
  申请人：GALECTO BIOTECH AB

  公开号：WO2021001528A1

  公开（公告）日：2021-01-07

  The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and/or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; liver disorders.

  本发明涉及一种式（1）的D-半乳糖吡喃糖类化合物，其中吡喃糖环为α-D-半乳糖吡喃糖，这些化合物是高亲和力的galectin-1和/或galectin 3抑制剂，用于治疗炎症；纤维化；瘢痕形成；瘢痕增生；异常瘢痕形成；手术粘连；脓毒性休克；癌症；转移性癌症；自身免疫疾病；代谢紊乱；心脏病；心力衰竭；病理性血管生成；眼部疾病；动脉粥样硬化；代谢性疾病；糖尿病I型；糖尿病II型；胰岛素抵抗；舒张期心力衰竭；哮喘；肝脏疾病。
• [EN] TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE TERT-BUTYL (S)-2-(4-(PHÉNYL)-6H-THIÉNO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZÉPIN-6-YL) ACÉTATE ET COMPOSÉS APPARENTÉS UTILISÉS EN TANT QU'INHIBITEURS DE BROMODOMAINE BROMOD4 POUR LE TRAITEMENT DU CANCER
  申请人：GENENTECH INC

  公开号：WO2020055976A1

  公开（公告）日：2020-03-19

  The present disclosure relates to te rt-butyl (S)-2-(4-(phenyl)-6H-thieno[3,2-f][l,2,4]triazolo[4,3-a] [l,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer. Exemplary compounds are e.g. tert-butyl (S)-2-(4-(4-(3-aminoprop-l-yn-l-yl)phenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][l,2,4]triazolo[4,3-a][l,4]diazepin-6-yl)acetate (example 1, compound la), tert-butyl(S,E)-2-(4-(4-(3-aminoprop-l-en-l-yl)phenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][l,2,4]triazolo[4,3-a][l,4]diazepin-6-yl)acetate (example 6, compound 6a) or tert-butyl(S)-2-(4-(4-(3-(hydroxyamino)prop-l-yn-l-yl)phenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][l,2,4]triazolo[4,3-a] [l,4]diazepin-6-yl)acetate (example 8, compound 8a).Results of biological assays, such as e.g. BRD4 BD1 and BD2 binding (table 2), cell proliferation assays (table 6) and inhibition of MYC expression in MV-4-11 cells (table 7) are disclosed.

  本公开涉及对叔丁基(S)-2-(4-(苯基)-6H-噻吩[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂蒽啉-6-基)醋酸酯衍生物及相关化合物作为治疗癌症的溴结构域BRD4抑制剂。示例化合物包括叔丁基(S)-2-(4-(4-(3-氨基丙-1-炔-1-基)苯基)-2,3,9-三甲基-6H-噻吩[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂蒽啉-6-基)醋酸酯（示例1，化合物la）、叔丁基(S,E)-2-(4-(4-(3-氨基丙-1-烯-1-基)苯基)-2,3,9-三甲基-6H-噻吩[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂蒽啉-6-基)醋酸酯（示例6，化合物6a）或叔丁基(S)-2-(4-(4-(3-(羟胺基)丙-1-炔-1-基)苯基)-2,3,9-三甲基-6H-噻吩[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂蒽啉-6-基)醋酸酯（示例8，化合物8a）。公开了生物测定的结果，例如BRD4 BD1和BD2结合（表2）、细胞增殖测定（表6）以及在MV-4-11细胞中MYC表达的抑制（表7）。